MFT 279

structure given in first source; (check-digit error in RN given in article 124070-28-3)

Also Known As:

3-(N-(2-chlorobenzyl)amino)-6-(1H-imidazol-1-yl)pyridazine dihydrochloride; MFT-279

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Neoplasms (Cancer) 08/01/1995 - "In pregnant mares' serum gonadotropin (PMSG)-treated female rats, the elevation of ovarian aromatase activity was significantly suppressed by the oral treatment with MFT-279 at 10 and 20 mg/kg. When MFT-279 (20 mg/kg) was orally given to 9,10-dimethyl-1,2-benzanthracene (DMBA)-treated female rats once a day for 28 days, regression of tumors was observed. "
2.	Carcinoma (Carcinomatosis) 08/01/1995 - "These results suggest that MFT-279 may be useful for the endocrine therapy of hormone dependent mammary carcinoma."

1.	Therapeutics